Cardiovascular–Kidney–Metabolic Syndrome Severity and Risk of Pancreatic Cancer in a Large Prospective Cohort
Diabetes/Metabolism Research and Reviews · 2026
DOI: 10.1002/dmrr.70214 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes/Metabolism Research and Reviews, 2026. Verfasst von Munseok Choi und 3 weiteren Autor:innen. Beteiligte Einrichtung: Division of HBP Surgery, Department of Surgery, Yonsei University College of Medicine, Yongin Severance Hospital, Yongin, Republic of Korea. Hauptthemen laut MEDLINE: Pancreatic Neoplasms, Metabolic Syndrome, Cardiovascular Diseases, Kidney Diseases. Die Arbeit nennt 36 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Yonsei University College of Medicine.
Abstract (Originalsprache)
Aims
Pancreatic cancer remains one of the most lethal malignancies due to late diagnosis and limited opportunities for prevention. Cardiovascular–kidney–metabolic (CKM) syndrome reflects the cumulative burden of metabolic, renal, and cardiovascular dysfunction, but its association with pancreatic cancer risk has not been well established. We investigated this relationship in a large prospective cohort from the UK Biobank. Materials and Methods Participants without pancreatic cancer at baseline (2006–2010) were followed through national cancer and mortality registries until 31 December 2022. CKM syndrome was categorised into five stages (0–4) according to American Heart Association criteria. Incident pancreatic cancer was identified using ICD‐9 and ICD‐10 codes. Fine–Gray subdistribution hazard models accounting for death were used to estimate subdistribution hazard ratios (SHRs) and 95% confidence intervals (CIs), with prespecified subgroup analyses performed.
Results
Among 326,148 participants, 1234 incident pancreatic cancer cases were identified over a mean follow‐up of 13.5 years (SD 2.0). Incidence rates increased progressively from 9.0 to 48.6 per 100,000 person‐years across CKM stages. Compared with CKM stage 0, multivariable‐adjusted SHRs for pancreatic cancer were 1.97 (95% CI 1.28–3.02) for stage 1, 2.02 (1.42–2.87) for stage 2, and 2.08 (1.42–3.04) for stages 3–4 ( p for trend < 0.001). Associations were generally consistent across subgroup analyses according to age, sex, smoking status, and alcohol consumption, without statistically significant interaction effects.
Conclusions
Advanced CKM syndrome was independently associated with higher pancreatic cancer risk, supporting its potential role in risk stratification and early detection strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Division of HBP Surgery, Department of Surgery, Yonsei University College of Medicine, Yongin Severance Hospital, Yongin, Republic of Korea.
- Department of Biomedical Systems Informatics, Yonsei University College of Medicine, Seoul, Republic of Korea.
- Department of Family Medicine, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
- Division of HBP Surgery, Department of Surgery, Yonsei University College of Medicine, Severance Hospital, Seoul, Republic of Korea.
ORCID-Profile: Munseok Choi, Seok-Jae Heo, Yu-Jin Kwon, Chang Moo Kang
Förderung
- Yonsei University College of Medicine
Zitieren
APA
Choi, M., Heo, S. J., Kwon, Y. J., & Kang, C. M. (2026). Cardiovascular–Kidney–Metabolic Syndrome Severity and Risk of Pancreatic Cancer in a Large Prospective Cohort. Diabetes/Metabolism Research and Reviews. https://doi.org/10.1002/dmrr.70214
Vancouver
Choi M, Heo SJ, Kwon YJ, Kang CM. Cardiovascular–Kidney–Metabolic Syndrome Severity and Risk of Pancreatic Cancer in a Large Prospective Cohort. Diabetes/Metabolism Research and Reviews. 2026. doi:10.1002/dmrr.70214
BibTeX
@article{Choi2026,
author = {Choi, Munseok and Heo, Seok-Jae and Kwon, Yu-Jin and Kang, Chang Moo},
title = {Cardiovascular–Kidney–Metabolic Syndrome Severity and Risk of Pancreatic Cancer in a Large Prospective Cohort},
journal = {Diabetes/Metabolism Research and Reviews},
year = {2026},
doi = {10.1002/dmrr.70214}
}
EUVIMED